Delaware
|
|
001-35867
|
|
33-0903395
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
of incorporation)
|
|
|
|
|
2505 Meridian Parkway, Suite 100
Durham, NC
|
|
27713
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
CMRX
|
The Nasdaq Global Market
|
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
Robert J. Meyer, M.D.
|
28,778,425
|
300,624
|
11,082,284
|
Michael Sherman
|
28,985,545
|
93,504
|
11,082,284
|
Votes For
|
40,036,660
|
Votes Against
|
101,909
|
Abstentions
|
22,764
|
Broker Non-Votes
|
—
|
|
Chimerix, Inc.
|
||
|
|
|
|
Dated: June 15, 2020
|
|
|
|
|
|
By:
|
/s/ Michael T. Andriole
|
|
|
|
Michael T. Andriole
|
|
|
|
Chief Business and Financial Officer
|